Literature DB >> 19041825

Molecular pathology of thyroid cancer: diagnostic and clinical implications.

James A Fagin1, Nicholas Mitsiades.   

Abstract

There is now a reasonably good understanding of the key oncogenic events involved in the initiation and progression of thyroid cancer. Many of these are characteristic of certain tumor types, and their presence conveys diagnostic and prognostic information. It is not yet clear how this information will be applied to clinical practice. Based on preclinical evidence, mutations of genes encoding certain kinases may also predict response to specific tyrosine kinase inhibitors, although this has not yet been explored systematically in clinical trials.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19041825      PMCID: PMC2615540          DOI: 10.1016/j.beem.2008.09.017

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  117 in total

1.  A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression.

Authors:  Janete M Cerutti; Rosana Delcelo; Marcelo João Amadei; Claudia Nakabashi; Rui M B Maciel; Bercedis Peterson; Jennifer Shoemaker; Gregory J Riggins
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

2.  The PAX8/PPARgamma fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPARgamma inhibition.

Authors:  J Gregory Powell; Xiying Wang; Brandon L Allard; Mustafa Sahin; Xiao-Li Wang; Ian D Hay; Henry J Hiddinga; Seema S Deshpande; Todd G Kroll; Stefan K G Grebe; Norman L Eberhardt; Bryan McIver
Journal:  Oncogene       Date:  2004-04-29       Impact factor: 9.867

3.  High frequency of mutations of the PIK3CA gene in human cancers.

Authors:  Yardena Samuels; Zhenghe Wang; Alberto Bardelli; Natalie Silliman; Janine Ptak; Steve Szabo; Hai Yan; Adi Gazdar; Steven M Powell; Gregory J Riggins; James K V Willson; Sanford Markowitz; Kenneth W Kinzler; Bert Vogelstein; Victor E Velculescu
Journal:  Science       Date:  2004-03-11       Impact factor: 47.728

Review 4.  Mitochondrial DNA and human thyroid diseases.

Authors:  Tatiana Rogounovitch; Vladimir Saenko; Shunichi Yamashita
Journal:  Endocr J       Date:  2004-06       Impact factor: 2.349

5.  Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules.

Authors:  Yoram Cohen; Eli Rosenbaum; Douglas P Clark; Martha A Zeiger; Christopher B Umbricht; Ralph P Tufano; David Sidransky; William H Westra
Journal:  Clin Cancer Res       Date:  2004-04-15       Impact factor: 12.531

6.  Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer.

Authors:  Milo Frattini; Cristina Ferrario; Paola Bressan; Debora Balestra; Loris De Cecco; Piera Mondellini; Italia Bongarzone; Paola Collini; Manuela Gariboldi; Silvana Pilotti; Marco A Pierotti; Angela Greco
Journal:  Oncogene       Date:  2004-09-23       Impact factor: 9.867

7.  Oncogenic B-Raf mutations: crystal clear at last.

Authors:  Amardeep S Dhillon; Walter Kolch
Journal:  Cancer Cell       Date:  2004-04       Impact factor: 31.743

8.  BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas.

Authors:  Efisio Puxeddu; Sonia Moretti; Rossella Elisei; Cristina Romei; Raffaela Pascucci; Marco Martinelli; Cecilia Marino; Nicola Avenia; Esther Diana Rossi; Guido Fadda; Antonio Cavaliere; Rodolfo Ribacchi; Alberto Falorni; Alfredo Pontecorvi; Furio Pacini; Aldo Pinchera; Fausto Santeusanio
Journal:  J Clin Endocrinol Metab       Date:  2004-05       Impact factor: 5.958

9.  BRAF mutations are associated with some histological types of papillary thyroid carcinoma.

Authors:  Vítor Trovisco; Inês Vieira de Castro; Paula Soares; Valdemar Máximo; Paula Silva; João Magalhães; Alexander Abrosimov; Xavier Matias Guiu; Manuel Sobrinho-Simões
Journal:  J Pathol       Date:  2004-02       Impact factor: 7.996

10.  Underexpression of peroxisome proliferator-activated receptor (PPAR)gamma in PAX8/PPARgamma-negative thyroid tumours.

Authors:  A R Marques; C Espadinha; M J Frias; L Roque; A L Catarino; L G Sobrinho; V Leite
Journal:  Br J Cancer       Date:  2004-08-16       Impact factor: 7.640

View more
  45 in total

1.  Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouse.

Authors:  Roch-Philippe Charles; Gioia Iezza; Elena Amendola; David Dankort; Martin McMahon
Journal:  Cancer Res       Date:  2011-04-21       Impact factor: 12.701

Review 2.  Thyroid stem cells--danger or resource?

Authors:  B Gibelli; Ama El-Fattah; G Giugliano; M Proh; E Grosso
Journal:  Acta Otorhinolaryngol Ital       Date:  2009-12       Impact factor: 2.124

3.  Quantitative analysis of suspicious thyroid nodules by contrast-enhanced ultrasonography.

Authors:  Yizhou Hu; Ping Li; Shufei Jiang; Fenghua Li
Journal:  Int J Clin Exp Med       Date:  2015-07-15

Review 4.  Synchronous occurrence of medullary and papillary carcinoma of the thyroid in a patient with cutaneous melanoma: determination of BRAFV600E in peripheral blood and tissues. Report of a case and review of the literature.

Authors:  Benedetta Fibbi; Pamela Pinzani; Francesca Salvianti; Matteo Rossi; Luisa Petrone; Maria Laura De Feo; Roberto Panconesi; Vania Vezzosi; Simonetta Bianchi; Gabriele Simontacchi; Monica Mangoni; Maurizio Pertici; Gianni Forti; Cinzia Pupilli
Journal:  Endocr Pathol       Date:  2014-09       Impact factor: 3.943

5.  Reduced expression of THRβ in papillary thyroid carcinomas: relationship with BRAF mutation, aggressiveness and miR expression.

Authors:  F Rosignolo; V Maggisano; M Sponziello; M Celano; C R T Di Gioia; M D'Agostino; L Giacomelli; A Verrienti; M Dima; V Pecce; C Durante
Journal:  J Endocrinol Invest       Date:  2015-05-24       Impact factor: 4.256

6.  Differential expression of a set of genes in follicular and classic variants of papillary thyroid carcinoma.

Authors:  Yusuf Ziya Igci; Ahmet Arslan; Ersin Akarsu; Suna Erkilic; Mehri Igci; Serdar Oztuzcu; Beyhan Cengiz; Bulent Gogebakan; Ecir Ali Cakmak; A Tuncay Demiryurek
Journal:  Endocr Pathol       Date:  2011-06       Impact factor: 3.943

Review 7.  Standard and emerging therapies for metastatic differentiated thyroid cancer.

Authors:  Christine J O'Neill; Jennifer Oucharek; Diana Learoyd; Stan B Sidhu
Journal:  Oncologist       Date:  2010-02-08

Review 8.  New developments in the diagnosis and treatment of thyroid cancer.

Authors:  David F Schneider; Herbert Chen
Journal:  CA Cancer J Clin       Date:  2013-06-24       Impact factor: 508.702

9.  STAT3 negatively regulates thyroid tumorigenesis.

Authors:  Joana Pinto Couto; Laura Daly; Ana Almeida; Jeffrey A Knauf; James A Fagin; Manuel Sobrinho-Simões; Jorge Lima; Valdemar Máximo; Paula Soares; David Lyden; Jacqueline F Bromberg
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-13       Impact factor: 11.205

10.  Association between CTLA-4 + 49A > G and - 318C > T single-nucleotide polymorphisms and susceptibility to thyroid neoplasm.

Authors:  Shabnam Abtahi; Fatemeh Izadi Jahromi; Mohammad Hossein Dabbaghmanesh; Mahyar Malekzadeh; Abbas Ghaderi
Journal:  Endocrine       Date:  2018-08-04       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.